• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Holuka Eugene Myron

    12/16/24 4:09:27 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTOR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Holuka Eugene Myron

    (Last) (First) (Middle)
    C/O CITIUS ONCOLOGY, INC.
    11 COMMERCE DRIVE, 1ST FLOOR

    (Street)
    CRANFORD NJ 07016

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CITIUS ONCOLOGY, INC. [ CTOR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/12/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.07 12/12/2024 A 125,000 (1) 12/12/2034 Common Stock 125,000 $0 125,000 D
    Stock Option (Right to Buy) $2.15 (2) 07/05/2033 Common Stock 150,000 150,000 D
    Explanation of Responses:
    1. The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.
    2. These options are 100% vested.
    /s/ Lorna A. Knick, by Power of Attorney 12/16/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CTOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTOR

    DatePrice TargetRatingAnalyst
    11/27/2024$3.00Buy
    Maxim Group
    More analyst ratings

    $CTOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

      CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025. "In Q2 2025, Citius Oncology advanced its transformation from a development-stage company to a commercial-stage organization. Following FDA approval of LYMPHIR, we intensified our focus on disciplined capital deployment and operational execu

      5/14/25 4:30:00 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

      CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) and its oncology subsidiary, Citius Oncology, Inc. (NASDAQ:CTOR), today announced that Leonard Mazur, Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York City. Conference Details:                Presentation: 3:10 pm ET on Thursday, June 5, 2025* Location: New York City Webcast: A live and archived webcast of the presentation will be available here.    A replay will be available for a limited time following the presentation on

      5/5/25 8:37:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

      CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fiscal First Quarter 2025 Business Highlights and Subsequent Developments Engaged Jefferies as exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value, with multiple active discussi

      2/14/25 4:30:00 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mayersohn Joel David

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 5:05:14 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Holuka Eugene Myron

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 4:09:27 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Secretary Holubiak Myron Z

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 4:09:06 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Citius Oncology with a new price target

      Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00

      11/27/24 8:17:22 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Citius Oncology Inc.

      10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      5/14/25 4:30:51 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      5/14/25 4:30:38 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Oncology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      4/25/25 4:15:29 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Financials

    Live finance-specific insights

    See more
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

      Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

      12/27/24 5:00:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

      SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      11/6/24 5:08:07 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

      SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      9/5/24 9:23:54 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Citius Oncology Inc.

      SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/16/24 4:34:29 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care